Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Helius Medical Technologies, Inc. - Class A Common Stock (NQ:HSDT)

0.3237 +0.0037 (+1.16%)
Streaming Delayed Price Updated: 10:32 AM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Helius Medical Technologies, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. (NASDAQ: HSDT) Featured in Coverage of the 37th Annual ROTH Conference
Via Investor Brand Network
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
Initial order placed with Company’s distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
Management to host business update call today at 9:00am ET 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Dane Andreeff, CEO of Helius Medical Technologies Inc. (NASDAQ: HSDT), to Present at NobleCon20
Via Investor Brand Network
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
Company to host call at 4:30pm today 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
From Helius Medical Technologies, Inc.
Via GlobeNewswire
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference
Via ACCESSWIRE
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
Company to host call at 4:30pm today 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Inc. (NASDAQ: HSDT) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.